Cediranib Plus Olaparib for Non-Germline BRCA-Mutated, Platinum-Resistant, Recurrent Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial
Clin. Cancer Res 2022 Aug 02;[EPub Ahead of Print], JM Lee, RG Moore, S Ghamande, MS Park, JP Diaz, J Chapman, J Kendrick, BM Slomovitz, KS Tewari, ES Lowe, T Milenkova, S Kumar, M Dymond, J Brown, JF LiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.